Editor’s Note: Welcome to “Let's Chat,” a blog series featuring contributions from members of the ophthalmic community.
This article was reviewed by Gairik Kundu, MBBS, MS
“All fluorometholones are not the same,” said Beeran Meghpara, MD, and with good reason.
Novel therapeutic approaches and drug-delivery technologies are improving control of pain and inflammation after cataract and other ocular surgeries.
Ocular surface inflammation may sound simple and specific but actually encompasses more than meets the eye.
Dry eye disease (DED) is far from being a single disease. Rather, it encompasses many different entities.
Technology and innovation has improved many aspects of health care and eye care, including ocular aesthetics.
Manufacturers’ global revenues for dry eye treatments is expected to top $6 billion in 2023.